Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors

“…The FDA-approved mineralocorticoid receptor (MR) antagonist spironolactone (SP) is used to treat a variety of disparate conditions ranging from heart failure to high blood pressure [223]. Interestingly, recent in vitro cell-based drug repurposing screens have identified SP as a compound with additional functions such as inhibiting DNA repair [224] and viral infection [225]. SP acts by rapidly degrading XPB protein [226], and it was shown that SP inhibits acute HIV and HIV-2 transcription without affecting cell viability in cell lines and primary CD4 + T cells [227].…”